Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Company Deals

Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025
Company Deals

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing

Fineline Cube Dec 15, 2025
Company Deals

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025
Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Policy / Regulatory

China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028

Fineline Cube Dec 15, 2025
Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Fineline Cube Dec 15, 2025
Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Fineline Cube Dec 15, 2025
Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Company

Zai Lab Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 2, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...

Company Deals

Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development

Fineline Cube Mar 2, 2023

Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...

Company Drug

Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study

Fineline Cube Mar 2, 2023

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...

Company Deals

Glowe Raises Series A+ Funding to Expand AIGC in Mental Health

Fineline Cube Mar 2, 2023

Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions”...

Company Deals

Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production

Fineline Cube Mar 2, 2023

Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia

Fineline Cube Mar 2, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Deals

BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results

Fineline Cube Mar 1, 2023

BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...

Company

Viatris Reports Q4 2022 Results, Highlights China Growth

Fineline Cube Mar 1, 2023

US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...

Company Medical Device

China Performs First AB-BNCT Procedures Outside Japan

Fineline Cube Mar 1, 2023

The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...

Company

HutchMed Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...

Company Drug

3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...

Company Deals

3SBio Terminates Distribution Agreement with AstraZeneca for Byetta

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...

Company Drug

JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma

Fineline Cube Mar 1, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company

FibroGen Reports Q4 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...

Policy / Regulatory R&D

China Issues New Ethical Review Measures for Life Sciences and Medical Research

Fineline Cube Mar 1, 2023

The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...

Company

Bayer Reports 2022 Sales Growth, Highlights New Drug Performances

Fineline Cube Mar 1, 2023

Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...

Policy / Regulatory

China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access

Fineline Cube Mar 1, 2023

The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1,...

Policy / Regulatory

China’s State Council Unveils Plan for TCM Revitalization and Development

Fineline Cube Mar 1, 2023

The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects...

Posts pagination

1 … 488 489 490 … 597

Recent updates

  • Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline
  • GSK’s Nucala Wins CHMP Nod for COPD in Europe
  • Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
  • Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
  • Innovent’s Mazdutide Wins Macau Approval for Weight Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Company Drug

Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.